Ferring patents expiration
1. Desmopressin Acetate patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7022340 | FERRING | Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
Apr, 2023
(1 year, 4 days ago) | |
Drugs and Companies using DESMOPRESSIN ACETATE ingredient
Market Authorisation Date: 08 May, 2008
Treatment: NA
Dosage: TABLET;ORAL
DESMOPRESSIN ACETATE family patents
2. Endometrin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7300664 | FERRING | Vaginally administrable progesterone-containing tablets and method for preparing same |
Nov, 2019
(4 years ago) | |
| US7320800 | FERRING | Vaginally administrable progesterone-containing tablets and method for preparing same |
Nov, 2019
(4 years ago) | |
| US7393543 | FERRING | Vaginally administratable progesterone-containing tablets and method for preparing same |
Nov, 2019
(4 years ago) | |
Drugs and Companies using PROGESTERONE ingredient
Market Authorisation Date: 21 June, 2007
Treatment: Support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women; Endometrin is a...
Dosage: INSERT;VAGINAL
ENDOMETRIN family patents
3. Firmagon patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5925730 | FERRING | GnRH antagonists |
May, 2021
(2 years ago) | |
| US10973870 | FERRING | Methods of treating prostate cancer with GnRH antagonist |
Feb, 2029
(4 years from now) | |
| US10729739 | FERRING | Methods of treating prostate cancer with GnRH antagonist |
Feb, 2029
(4 years from now) | |
| US9579359 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Feb, 2029
(4 years from now) | |
| US11826397 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Apr, 2032
(7 years from now) | |
| US9415085 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Apr, 2032
(7 years from now) | |
| US10695398 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Apr, 2032
(7 years from now) | |
| US11766468 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Apr, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 24, 2013 |
Drugs and Companies using DEGARELIX ACETATE ingredient
NCE-1 date: 24 December, 2012
Market Authorisation Date: 24 December, 2008
Treatment: Gnrh antagonist indicated for treatment of patients with advanced prostate cancer; Treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist ...
Dosage: POWDER;SUBCUTANEOUS
FIRMAGON family patents